Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past. This golden age is also presenting tremendous opportunities for investors.
Biotech stocks offer the potential for substantial long-term returns. The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market. Our pick for the day ticks all of these boxes.
Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space.
So far, the company has remained enormously profitable and has continued expanding revenue within the CF market. Suppose management’s plans for expanded approvals for younger cohorts continue to come to fruition over the next few years. In that case, Vertex will eventually treat as many as 90% of all people with CF.
The company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and genetic hematologic disorders like sickle cell disease. In other words, even if it eventually corners the entire CF therapies market, there will still be other growth opportunities.
You might also like:
- Elon’s Greatest Invention… Hidden in South Memphis?
- Controversial White House-backed energy find
- White House to reset Social Security?
- New discovery: 30,000 years of all-American energy?
- This robot is coming to 65 million Americans … this year.
- Where to invest $1,000 right now…
- The Most Exciting Human Discovery Since Fire?
- Wall Street Icon: “If you wait on this, it will already be too late”…
- Major DOGE Panic Begins, April 30?
- The DOGE Shock: Nine Stocks to Take Advantage of Elon’s Next Move
